Mayumi Fujita
Concepts (406)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 30 | 2023 | 752 | 5.310 |
Why?
| Skin Neoplasms | 14 | 2021 | 833 | 2.100 |
Why?
| Neoplastic Stem Cells | 11 | 2020 | 386 | 1.920 |
Why?
| Interleukin-1 | 10 | 2022 | 961 | 1.720 |
Why?
| Aldehyde Dehydrogenase | 5 | 2019 | 105 | 1.520 |
Why?
| T-Lymphocytes, Regulatory | 6 | 2023 | 376 | 1.470 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2021 | 153 | 0.880 |
Why?
| Cysteine | 2 | 2020 | 188 | 0.880 |
Why?
| Inflammasomes | 3 | 2020 | 128 | 0.860 |
Why?
| Cell Transformation, Neoplastic | 2 | 2018 | 325 | 0.860 |
Why?
| Ultraviolet Rays | 4 | 2020 | 384 | 0.860 |
Why?
| Vitiligo | 4 | 2020 | 45 | 0.780 |
Why?
| Neoplasms, Second Primary | 1 | 2023 | 108 | 0.760 |
Why?
| Antineoplastic Agents | 10 | 2021 | 2060 | 0.760 |
Why?
| Aldehyde Oxidoreductases | 2 | 2019 | 29 | 0.760 |
Why?
| Keratinocytes | 4 | 2021 | 243 | 0.760 |
Why?
| Cell Line, Tumor | 19 | 2024 | 3184 | 0.750 |
Why?
| Forkhead Transcription Factors | 1 | 2022 | 182 | 0.750 |
Why?
| Nitric Oxide | 2 | 2019 | 886 | 0.740 |
Why?
| Mice | 33 | 2024 | 16644 | 0.730 |
Why?
| Skin | 4 | 2020 | 719 | 0.720 |
Why?
| Cryopyrin-Associated Periodic Syndromes | 1 | 2020 | 8 | 0.720 |
Why?
| Melanocytes | 7 | 2020 | 69 | 0.700 |
Why?
| Aldehyde Dehydrogenase, Mitochondrial | 1 | 2019 | 24 | 0.630 |
Why?
| Pancreatic Neoplasms | 2 | 2019 | 878 | 0.630 |
Why?
| Hyperpigmentation | 1 | 2019 | 26 | 0.610 |
Why?
| CDC2 Protein Kinase | 1 | 2018 | 31 | 0.610 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2020 | 313 | 0.600 |
Why?
| MicroRNAs | 2 | 2023 | 677 | 0.600 |
Why?
| Adenosine Triphosphate | 1 | 2020 | 471 | 0.590 |
Why?
| Catechin | 2 | 2024 | 26 | 0.590 |
Why?
| SOXB1 Transcription Factors | 1 | 2018 | 58 | 0.590 |
Why?
| Animals | 38 | 2024 | 34600 | 0.580 |
Why?
| Interleukin-1beta | 6 | 2021 | 374 | 0.550 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 343 | 0.540 |
Why?
| Drug Resistance, Neoplasm | 6 | 2020 | 750 | 0.540 |
Why?
| Phenotype | 3 | 2022 | 3058 | 0.540 |
Why?
| Neoplasm Invasiveness | 3 | 2019 | 480 | 0.520 |
Why?
| RNA, Messenger | 5 | 2019 | 2676 | 0.520 |
Why?
| Inflammation | 6 | 2019 | 2668 | 0.510 |
Why?
| Signal Transduction | 10 | 2021 | 4838 | 0.500 |
Why?
| Dendritic Cells | 4 | 2016 | 479 | 0.490 |
Why?
| Sulfonamides | 6 | 2020 | 500 | 0.480 |
Why?
| Skin Pigmentation | 3 | 2020 | 48 | 0.470 |
Why?
| Heavy Ion Radiotherapy | 1 | 2014 | 1 | 0.460 |
Why?
| Mice, Nude | 7 | 2021 | 683 | 0.460 |
Why?
| Nitrophenols | 5 | 2017 | 38 | 0.460 |
Why?
| Humans | 58 | 2024 | 129128 | 0.450 |
Why?
| Immune Tolerance | 2 | 2015 | 349 | 0.450 |
Why?
| Psoriasis | 3 | 2021 | 92 | 0.450 |
Why?
| Biphenyl Compounds | 5 | 2017 | 63 | 0.440 |
Why?
| Melanoma, Experimental | 2 | 2021 | 110 | 0.440 |
Why?
| rhoA GTP-Binding Protein | 1 | 2014 | 91 | 0.440 |
Why?
| Biomarkers, Tumor | 5 | 2021 | 1185 | 0.430 |
Why?
| Adaptive Immunity | 1 | 2014 | 161 | 0.420 |
Why?
| Retinal Dehydrogenase | 3 | 2019 | 33 | 0.420 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 7 | 2021 | 235 | 0.420 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 421 | 0.400 |
Why?
| Side-Population Cells | 1 | 2012 | 9 | 0.400 |
Why?
| Apoptosis | 10 | 2024 | 2438 | 0.400 |
Why?
| Proto-Oncogene Proteins B-raf | 4 | 2021 | 215 | 0.390 |
Why?
| Cell Separation | 1 | 2013 | 313 | 0.390 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 357 | 0.390 |
Why?
| Cytoskeletal Proteins | 1 | 2012 | 142 | 0.380 |
Why?
| Camellia sinensis | 1 | 2011 | 5 | 0.380 |
Why?
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 1353 | 0.380 |
Why?
| Polyphenols | 1 | 2011 | 18 | 0.380 |
Why?
| Neoplasm Proteins | 2 | 2021 | 421 | 0.370 |
Why?
| Complement C1q | 1 | 2011 | 38 | 0.370 |
Why?
| Desmoglein 3 | 1 | 2011 | 16 | 0.360 |
Why?
| Pemphigus | 1 | 2011 | 9 | 0.360 |
Why?
| Paraneoplastic Syndromes | 1 | 2011 | 12 | 0.360 |
Why?
| Ubiquitin | 1 | 2010 | 62 | 0.350 |
Why?
| Tumor Suppressor Protein p53 | 4 | 2011 | 508 | 0.350 |
Why?
| Histiocytosis | 1 | 2010 | 8 | 0.340 |
Why?
| Gene Expression Profiling | 3 | 2018 | 1689 | 0.340 |
Why?
| Caspase 2 | 1 | 2009 | 14 | 0.340 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2010 | 145 | 0.340 |
Why?
| Cannabidiol | 2 | 2022 | 91 | 0.330 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2020 | 43 | 0.330 |
Why?
| Disease Models, Animal | 8 | 2021 | 3953 | 0.330 |
Why?
| Naphthoquinones | 1 | 2009 | 19 | 0.320 |
Why?
| Ultraviolet Therapy | 2 | 2020 | 18 | 0.320 |
Why?
| Induced Pluripotent Stem Cells | 2 | 2024 | 224 | 0.320 |
Why?
| Carcinoma, Merkel Cell | 1 | 2009 | 19 | 0.320 |
Why?
| Carcinoma, Basal Cell | 1 | 2010 | 73 | 0.310 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2009 | 108 | 0.310 |
Why?
| Membrane Proteins | 3 | 2016 | 1109 | 0.300 |
Why?
| Radiation-Protective Agents | 1 | 2008 | 27 | 0.290 |
Why?
| Cell Proliferation | 6 | 2021 | 2347 | 0.290 |
Why?
| Imidazoles | 1 | 2009 | 229 | 0.290 |
Why?
| Dacarbazine | 3 | 2012 | 97 | 0.290 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 190 | 0.290 |
Why?
| Female | 24 | 2024 | 68518 | 0.280 |
Why?
| Xenograft Model Antitumor Assays | 6 | 2021 | 813 | 0.280 |
Why?
| Cytokines | 3 | 2022 | 1987 | 0.280 |
Why?
| Mice, Transgenic | 5 | 2021 | 2079 | 0.280 |
Why?
| Enzyme Activation | 3 | 2020 | 799 | 0.270 |
Why?
| Neoplasms | 2 | 2020 | 2475 | 0.260 |
Why?
| Receptors, Interleukin-1 | 4 | 2020 | 223 | 0.260 |
Why?
| Cancer Vaccines | 1 | 2007 | 165 | 0.260 |
Why?
| Models, Animal | 1 | 2008 | 367 | 0.260 |
Why?
| Nitric Oxide Synthase | 2 | 2019 | 232 | 0.260 |
Why?
| Cellular Reprogramming | 3 | 2024 | 95 | 0.250 |
Why?
| Point Mutation | 2 | 2024 | 224 | 0.250 |
Why?
| Carrier Proteins | 1 | 2009 | 732 | 0.250 |
Why?
| Neutrophils | 1 | 2011 | 1195 | 0.250 |
Why?
| NF-kappa B | 2 | 2024 | 652 | 0.240 |
Why?
| Mice, Hairless | 2 | 2020 | 61 | 0.240 |
Why?
| Immunity, Innate | 3 | 2016 | 805 | 0.240 |
Why?
| Isoenzymes | 2 | 2018 | 304 | 0.240 |
Why?
| Antigens, Neoplasm | 1 | 2007 | 310 | 0.240 |
Why?
| Cytosine | 1 | 2024 | 46 | 0.230 |
Why?
| Antioxidants | 1 | 2008 | 543 | 0.230 |
Why?
| Mice, Inbred C57BL | 6 | 2024 | 5284 | 0.220 |
Why?
| Prognosis | 3 | 2023 | 3788 | 0.220 |
Why?
| Active Transport, Cell Nucleus | 1 | 2024 | 113 | 0.220 |
Why?
| CpG Islands | 1 | 2024 | 152 | 0.220 |
Why?
| Dermatitis, Atopic | 2 | 2020 | 321 | 0.210 |
Why?
| Saccharomyces cerevisiae | 1 | 2007 | 525 | 0.210 |
Why?
| Up-Regulation | 2 | 2019 | 828 | 0.210 |
Why?
| CTLA-4 Antigen | 1 | 2023 | 89 | 0.200 |
Why?
| Dermatitis | 1 | 2022 | 20 | 0.200 |
Why?
| Jurkat Cells | 1 | 2022 | 131 | 0.200 |
Why?
| Kaplan-Meier Estimate | 2 | 2019 | 864 | 0.200 |
Why?
| Australia | 1 | 2023 | 246 | 0.200 |
Why?
| Receptor, EphB4 | 1 | 2022 | 36 | 0.200 |
Why?
| Mutation | 5 | 2020 | 3700 | 0.190 |
Why?
| Ephrin-B2 | 1 | 2022 | 50 | 0.190 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2024 | 227 | 0.190 |
Why?
| Flow Cytometry | 3 | 2015 | 1142 | 0.190 |
Why?
| AMP-Activated Protein Kinases | 1 | 2023 | 190 | 0.190 |
Why?
| Chemotaxis | 2 | 2014 | 130 | 0.190 |
Why?
| Leukemia | 1 | 2024 | 229 | 0.190 |
Why?
| CD8-Positive T-Lymphocytes | 4 | 2024 | 847 | 0.190 |
Why?
| Hair Follicle | 2 | 2020 | 45 | 0.190 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 42 | 0.180 |
Why?
| MAP Kinase Kinase 1 | 1 | 2021 | 76 | 0.180 |
Why?
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 39 | 0.180 |
Why?
| Alcohol Oxidoreductases | 1 | 2021 | 49 | 0.180 |
Why?
| Anti-Inflammatory Agents | 2 | 2022 | 471 | 0.180 |
Why?
| Male | 15 | 2020 | 63202 | 0.180 |
Why?
| Protein Interaction Maps | 1 | 2020 | 44 | 0.180 |
Why?
| Pruritus | 1 | 2020 | 59 | 0.170 |
Why?
| RNA, Small Interfering | 2 | 2012 | 571 | 0.170 |
Why?
| Adult Stem Cells | 1 | 2020 | 39 | 0.170 |
Why?
| S Phase Cell Cycle Checkpoints | 1 | 2020 | 5 | 0.170 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 8 | 0.170 |
Why?
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 63 | 0.170 |
Why?
| Leupeptins | 2 | 2010 | 11 | 0.170 |
Why?
| Cell Plasticity | 1 | 2020 | 27 | 0.170 |
Why?
| Proteasome Inhibitors | 2 | 2010 | 44 | 0.170 |
Why?
| Interleukin-1 Receptor Accessory Protein | 1 | 2019 | 8 | 0.160 |
Why?
| Antibodies, Blocking | 1 | 2019 | 33 | 0.160 |
Why?
| Aniline Compounds | 1 | 2020 | 98 | 0.160 |
Why?
| beta Catenin | 2 | 2020 | 219 | 0.160 |
Why?
| Tail | 1 | 2019 | 29 | 0.160 |
Why?
| DNA Methylation | 1 | 2024 | 605 | 0.160 |
Why?
| Piperazines | 6 | 2021 | 337 | 0.160 |
Why?
| Nitrofurans | 1 | 2018 | 1 | 0.160 |
Why?
| Peritonitis | 1 | 2019 | 80 | 0.160 |
Why?
| Hydroxybenzoates | 1 | 2018 | 11 | 0.160 |
Why?
| Interleukins | 1 | 2020 | 245 | 0.160 |
Why?
| Phosphorylation | 2 | 2024 | 1687 | 0.150 |
Why?
| Cell Line | 2 | 2024 | 2737 | 0.150 |
Why?
| Tumor Microenvironment | 3 | 2024 | 622 | 0.150 |
Why?
| Fluorescent Antibody Technique | 1 | 2019 | 374 | 0.150 |
Why?
| Heterografts | 1 | 2018 | 129 | 0.150 |
Why?
| Histones | 1 | 2023 | 584 | 0.150 |
Why?
| Aged | 7 | 2020 | 22090 | 0.150 |
Why?
| Lung Neoplasms | 1 | 2011 | 2329 | 0.140 |
Why?
| Zinc Finger Protein GLI1 | 1 | 2017 | 24 | 0.140 |
Why?
| Congresses as Topic | 1 | 2019 | 215 | 0.140 |
Why?
| Neoplasm Staging | 2 | 2012 | 1293 | 0.140 |
Why?
| Head and Neck Neoplasms | 1 | 2022 | 534 | 0.140 |
Why?
| MAP Kinase Signaling System | 1 | 2019 | 303 | 0.140 |
Why?
| Protein Transport | 1 | 2018 | 422 | 0.140 |
Why?
| Stress, Physiological | 1 | 2020 | 412 | 0.140 |
Why?
| Biopsy | 2 | 2011 | 1086 | 0.140 |
Why?
| Haptens | 2 | 2014 | 22 | 0.130 |
Why?
| Transforming Growth Factor beta | 1 | 2019 | 449 | 0.130 |
Why?
| Drug Therapy, Combination | 2 | 2016 | 1013 | 0.130 |
Why?
| Dermatitis, Contact | 2 | 2014 | 19 | 0.130 |
Why?
| Drug Synergism | 5 | 2017 | 358 | 0.130 |
Why?
| Diagnosis, Differential | 2 | 2011 | 1417 | 0.130 |
Why?
| Cell Survival | 3 | 2017 | 1077 | 0.130 |
Why?
| Computational Biology | 1 | 2020 | 598 | 0.130 |
Why?
| Tumor Cells, Cultured | 2 | 2021 | 930 | 0.130 |
Why?
| Overweight | 1 | 2020 | 526 | 0.130 |
Why?
| Mice, Knockout | 2 | 2021 | 2765 | 0.130 |
Why?
| T-Lymphocytes | 1 | 2024 | 1924 | 0.120 |
Why?
| Biomedical Research | 2 | 2019 | 647 | 0.120 |
Why?
| Cytotoxicity, Immunologic | 2 | 2024 | 218 | 0.120 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 616 | 0.120 |
Why?
| B-Lymphocytes | 1 | 2020 | 823 | 0.120 |
Why?
| Dinitrofluorobenzene | 1 | 2014 | 7 | 0.120 |
Why?
| Fenretinide | 1 | 2014 | 8 | 0.120 |
Why?
| Oligopeptides | 1 | 2016 | 258 | 0.120 |
Why?
| Ethanol | 1 | 2019 | 585 | 0.110 |
Why?
| Proteomics | 1 | 2020 | 1010 | 0.110 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 1423 | 0.110 |
Why?
| Caspases | 2 | 2012 | 242 | 0.110 |
Why?
| Pneumonia | 1 | 2019 | 599 | 0.110 |
Why?
| Cilia | 1 | 2015 | 179 | 0.110 |
Why?
| Stem Cells | 1 | 2017 | 579 | 0.100 |
Why?
| Viral Load | 1 | 2015 | 450 | 0.100 |
Why?
| Caspases, Initiator | 1 | 2012 | 18 | 0.100 |
Why?
| Phagocytosis | 1 | 2014 | 364 | 0.100 |
Why?
| CARD Signaling Adaptor Proteins | 1 | 2012 | 20 | 0.100 |
Why?
| Antibodies, Monoclonal | 1 | 2019 | 1359 | 0.100 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1573 | 0.100 |
Why?
| Proto-Oncogene Proteins | 2 | 2023 | 634 | 0.100 |
Why?
| Protein Binding | 1 | 2018 | 2106 | 0.100 |
Why?
| Response Elements | 1 | 2012 | 89 | 0.100 |
Why?
| Crystallins | 1 | 2012 | 51 | 0.100 |
Why?
| Coloring Agents | 1 | 2012 | 76 | 0.100 |
Why?
| Vaccinia | 1 | 2012 | 22 | 0.100 |
Why?
| Neoplasm Transplantation | 1 | 2012 | 258 | 0.100 |
Why?
| Cell Movement | 2 | 2014 | 939 | 0.100 |
Why?
| Molecular Targeted Therapy | 1 | 2015 | 387 | 0.100 |
Why?
| Vaccinia virus | 1 | 2012 | 43 | 0.100 |
Why?
| DNA Damage | 1 | 2014 | 364 | 0.100 |
Why?
| Cell Cycle | 1 | 2015 | 581 | 0.100 |
Why?
| Mice, SCID | 1 | 2012 | 347 | 0.090 |
Why?
| Tretinoin | 1 | 2012 | 128 | 0.090 |
Why?
| Alkylating Agents | 1 | 2011 | 24 | 0.090 |
Why?
| Gene Silencing | 1 | 2012 | 185 | 0.090 |
Why?
| Metabolic Diseases | 1 | 2012 | 107 | 0.090 |
Why?
| Cells, Cultured | 1 | 2019 | 4010 | 0.090 |
Why?
| Lens, Crystalline | 1 | 2012 | 100 | 0.090 |
Why?
| Models, Biological | 1 | 2018 | 1695 | 0.090 |
Why?
| Paclitaxel | 1 | 2012 | 215 | 0.090 |
Why?
| Interleukin-8 | 1 | 2012 | 258 | 0.090 |
Why?
| Genes, p16 | 1 | 2010 | 20 | 0.090 |
Why?
| Half-Life | 1 | 2010 | 144 | 0.090 |
Why?
| Mice, Inbred NOD | 1 | 2012 | 584 | 0.090 |
Why?
| Biomimetic Materials | 1 | 2011 | 72 | 0.090 |
Why?
| G1 Phase | 1 | 2010 | 71 | 0.090 |
Why?
| Mast Cells | 1 | 2012 | 142 | 0.090 |
Why?
| Transfection | 3 | 2008 | 896 | 0.090 |
Why?
| Fatal Outcome | 1 | 2011 | 301 | 0.090 |
Why?
| Etoposide | 1 | 2010 | 150 | 0.090 |
Why?
| In Vitro Techniques | 1 | 2012 | 1044 | 0.090 |
Why?
| Lactones | 1 | 2010 | 58 | 0.090 |
Why?
| Lymphatic Metastasis | 1 | 2011 | 318 | 0.090 |
Why?
| Protein Stability | 1 | 2010 | 161 | 0.090 |
Why?
| DNA Primers | 1 | 2011 | 510 | 0.080 |
Why?
| Protease Inhibitors | 1 | 2010 | 104 | 0.080 |
Why?
| Gene Expression | 1 | 2015 | 1462 | 0.080 |
Why?
| Recombinant Proteins | 2 | 2015 | 1284 | 0.080 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 45 | 0.080 |
Why?
| Gene Deletion | 1 | 2010 | 372 | 0.080 |
Why?
| Breast Neoplasms | 1 | 2021 | 2150 | 0.080 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 940 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 757 | 0.080 |
Why?
| Interleukin-6 | 3 | 2020 | 718 | 0.080 |
Why?
| Middle Aged | 5 | 2020 | 31080 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 816 | 0.080 |
Why?
| Knee | 1 | 2009 | 60 | 0.080 |
Why?
| Quality of Life | 1 | 2020 | 2694 | 0.080 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2008 | 48 | 0.080 |
Why?
| Biopsy, Needle | 1 | 2009 | 189 | 0.080 |
Why?
| Rare Diseases | 1 | 2009 | 103 | 0.080 |
Why?
| Pyrroles | 2 | 2021 | 192 | 0.080 |
Why?
| Cardiovascular Diseases | 1 | 2020 | 2024 | 0.070 |
Why?
| Genes, ras | 1 | 2008 | 98 | 0.070 |
Why?
| Lymph Node Excision | 1 | 2009 | 165 | 0.070 |
Why?
| Diabetic Foot | 1 | 2008 | 26 | 0.070 |
Why?
| Neovascularization, Pathologic | 1 | 2009 | 291 | 0.070 |
Why?
| MART-1 Antigen | 1 | 2007 | 13 | 0.070 |
Why?
| Immunohistochemistry | 2 | 2009 | 1671 | 0.070 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2007 | 42 | 0.070 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2008 | 182 | 0.070 |
Why?
| Base Sequence | 1 | 2011 | 2135 | 0.070 |
Why?
| Genetic Predisposition to Disease | 1 | 2016 | 2267 | 0.070 |
Why?
| Cell Self Renewal | 2 | 2017 | 54 | 0.070 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 147 | 0.070 |
Why?
| Macrophages | 2 | 2015 | 1466 | 0.070 |
Why?
| Immunoglobulin G | 1 | 2011 | 846 | 0.070 |
Why?
| Thioridazine | 1 | 2006 | 2 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2020 | 4915 | 0.060 |
Why?
| Dermatitis, Photoallergic | 1 | 2006 | 4 | 0.060 |
Why?
| Erythema | 1 | 2006 | 28 | 0.060 |
Why?
| Combined Modality Therapy | 1 | 2009 | 1209 | 0.060 |
Why?
| Dinitrobenzenes | 1 | 2005 | 6 | 0.060 |
Why?
| Spleen | 1 | 2007 | 513 | 0.060 |
Why?
| Down-Regulation | 2 | 2023 | 634 | 0.060 |
Why?
| Interleukin-12 | 1 | 2005 | 120 | 0.060 |
Why?
| Risk Assessment | 2 | 2015 | 3260 | 0.060 |
Why?
| Retroelements | 1 | 2024 | 45 | 0.060 |
Why?
| Interferon-gamma | 1 | 2007 | 762 | 0.060 |
Why?
| Granzymes | 1 | 2024 | 46 | 0.060 |
Why?
| Bcl-2-Like Protein 11 | 2 | 2017 | 40 | 0.050 |
Why?
| Case-Control Studies | 1 | 2011 | 3342 | 0.050 |
Why?
| Mixed Function Oxygenases | 1 | 2023 | 37 | 0.050 |
Why?
| Autoantibodies | 1 | 2011 | 1465 | 0.050 |
Why?
| ras Proteins | 1 | 2003 | 145 | 0.050 |
Why?
| Palmitic Acids | 1 | 2022 | 10 | 0.050 |
Why?
| Ethanolamines | 1 | 2022 | 18 | 0.050 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 2022 | 150 | 0.050 |
Why?
| Uveal Neoplasms | 1 | 2021 | 11 | 0.050 |
Why?
| Acetates | 1 | 2022 | 97 | 0.050 |
Why?
| Amides | 1 | 2022 | 92 | 0.050 |
Why?
| Edema | 1 | 2022 | 125 | 0.050 |
Why?
| Lipopolysaccharides | 2 | 2015 | 856 | 0.050 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2007 | 1048 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2003 | 501 | 0.040 |
Why?
| Aminopyridines | 1 | 2021 | 96 | 0.040 |
Why?
| Protein Structure, Tertiary | 2 | 2015 | 836 | 0.040 |
Why?
| Pyrimidinones | 1 | 2021 | 102 | 0.040 |
Why?
| Administration, Cutaneous | 1 | 2020 | 123 | 0.040 |
Why?
| Gels | 1 | 2020 | 83 | 0.040 |
Why?
| Treatment Outcome | 3 | 2020 | 10227 | 0.040 |
Why?
| HIV Infections | 1 | 2015 | 2715 | 0.040 |
Why?
| Potassium Channels, Voltage-Gated | 1 | 2020 | 48 | 0.040 |
Why?
| X-Rays | 1 | 2020 | 29 | 0.040 |
Why?
| Neoplasm Recurrence, Local | 2 | 2016 | 963 | 0.040 |
Why?
| Erythroblasts | 1 | 2020 | 16 | 0.040 |
Why?
| Antigens, CD19 | 1 | 2020 | 115 | 0.040 |
Why?
| rho GTP-Binding Proteins | 1 | 2020 | 62 | 0.040 |
Why?
| Pyridones | 1 | 2021 | 160 | 0.040 |
Why?
| A549 Cells | 1 | 2019 | 58 | 0.040 |
Why?
| Open Reading Frames | 1 | 2020 | 116 | 0.040 |
Why?
| Transcriptional Activation | 1 | 2021 | 356 | 0.040 |
Why?
| Societies, Scientific | 1 | 2019 | 46 | 0.040 |
Why?
| Interleukin-33 | 1 | 2019 | 49 | 0.040 |
Why?
| Ovalbumin | 1 | 2019 | 177 | 0.040 |
Why?
| Vaccination | 1 | 2007 | 1349 | 0.040 |
Why?
| Prodrugs | 1 | 2018 | 45 | 0.040 |
Why?
| Pigmentation | 1 | 2018 | 55 | 0.040 |
Why?
| Uric Acid | 1 | 2019 | 161 | 0.040 |
Why?
| Cell Division | 1 | 2020 | 779 | 0.040 |
Why?
| Risk | 1 | 2020 | 856 | 0.040 |
Why?
| Laser Capture Microdissection | 1 | 2017 | 22 | 0.040 |
Why?
| Pyridines | 1 | 2021 | 477 | 0.040 |
Why?
| Molecular Structure | 1 | 2018 | 466 | 0.030 |
Why?
| Gene Knockout Techniques | 1 | 2017 | 109 | 0.030 |
Why?
| Neurofibromin 1 | 1 | 2016 | 26 | 0.030 |
Why?
| HEK293 Cells | 1 | 2019 | 687 | 0.030 |
Why?
| GTP Phosphohydrolases | 1 | 2016 | 84 | 0.030 |
Why?
| Amyloid Precursor Protein Secretases | 1 | 2016 | 81 | 0.030 |
Why?
| Self Report | 1 | 2020 | 806 | 0.030 |
Why?
| Mice, Inbred BALB C | 2 | 2012 | 1230 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2016 | 2508 | 0.030 |
Why?
| Caspase 1 | 1 | 2016 | 142 | 0.030 |
Why?
| Toll-Like Receptors | 1 | 2016 | 179 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2017 | 428 | 0.030 |
Why?
| Immobilized Proteins | 1 | 2015 | 11 | 0.030 |
Why?
| Neutralization Tests | 1 | 2015 | 73 | 0.030 |
Why?
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 60 | 0.030 |
Why?
| Retinoids | 1 | 2014 | 34 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 88 | 0.030 |
Why?
| CD4 Lymphocyte Count | 1 | 2015 | 267 | 0.030 |
Why?
| Extracellular Space | 1 | 2015 | 120 | 0.030 |
Why?
| Complementary Therapies | 1 | 2015 | 86 | 0.030 |
Why?
| Cell Differentiation | 2 | 2015 | 1901 | 0.030 |
Why?
| Endotoxemia | 1 | 2015 | 84 | 0.030 |
Why?
| Young Adult | 2 | 2020 | 12389 | 0.030 |
Why?
| Adult | 4 | 2020 | 35513 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 269 | 0.030 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 266 | 0.030 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 371 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2020 | 2739 | 0.030 |
Why?
| Antigens, CD | 1 | 2015 | 483 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2015 | 538 | 0.020 |
Why?
| Cathelicidins | 1 | 2012 | 40 | 0.020 |
Why?
| Kaposi Varicelliform Eruption | 1 | 2012 | 22 | 0.020 |
Why?
| Survival Analysis | 1 | 2015 | 1265 | 0.020 |
Why?
| Antimicrobial Cationic Peptides | 1 | 2012 | 80 | 0.020 |
Why?
| Adoptive Transfer | 1 | 2012 | 217 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2017 | 1403 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2016 | 1825 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2015 | 1098 | 0.020 |
Why?
| Bone Marrow Cells | 1 | 2012 | 294 | 0.020 |
Why?
| Cohort Studies | 1 | 2020 | 5407 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2015 | 1192 | 0.020 |
Why?
| Immunization | 1 | 2012 | 412 | 0.020 |
Why?
| Anoikis | 1 | 2008 | 32 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2008 | 140 | 0.020 |
Why?
| Time Factors | 2 | 2011 | 6518 | 0.020 |
Why?
| In Situ Hybridization | 1 | 2008 | 292 | 0.020 |
Why?
| Arm | 1 | 2008 | 110 | 0.020 |
Why?
| Disease Progression | 1 | 2015 | 2613 | 0.020 |
Why?
| Cell Adhesion | 1 | 2008 | 445 | 0.020 |
Why?
| RNA Interference | 1 | 2008 | 441 | 0.020 |
Why?
| Dermatitis, Phototoxic | 1 | 2006 | 4 | 0.020 |
Why?
| Leg | 1 | 2008 | 242 | 0.020 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2006 | 133 | 0.020 |
Why?
| Electron Spin Resonance Spectroscopy | 1 | 2006 | 90 | 0.020 |
Why?
| Free Radicals | 1 | 2006 | 104 | 0.020 |
Why?
| Patch Tests | 1 | 2006 | 57 | 0.020 |
Why?
| Wound Healing | 1 | 2008 | 311 | 0.020 |
Why?
| Ascorbic Acid | 1 | 2006 | 125 | 0.020 |
Why?
| Epidermis | 1 | 2005 | 156 | 0.010 |
Why?
| Age Factors | 1 | 2012 | 3120 | 0.010 |
Why?
| Cross-Sectional Studies | 1 | 2015 | 5070 | 0.010 |
Why?
| Biomarkers | 1 | 2015 | 3896 | 0.010 |
Why?
| Lymph Nodes | 1 | 2005 | 467 | 0.010 |
Why?
| Cell Hypoxia | 1 | 2003 | 229 | 0.010 |
Why?
| Mitochondria | 1 | 2008 | 854 | 0.010 |
Why?
| Chronic Disease | 1 | 2008 | 1707 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2006 | 1945 | 0.010 |
Why?
| Adolescent | 1 | 2020 | 20302 | 0.010 |
Why?
| Cell Culture Techniques | 1 | 2003 | 346 | 0.010 |
Why?
| Child | 1 | 2020 | 20806 | 0.010 |
Why?
| Retrospective Studies | 1 | 2015 | 14571 | 0.010 |
Why?
|
|
Fujita's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|